Vis enkel innførsel

dc.contributor.authorDrakulic, Danijela
dc.contributor.authorDjurovic, Srdjan
dc.contributor.authorSyed, Yasir Ahmed
dc.contributor.authorTrattaro, Sebastiano
dc.contributor.authorCaporale, Nicolò
dc.contributor.authorFalk, Anna
dc.contributor.authorOfir, Rivka
dc.contributor.authorHeine, Vivi M.
dc.contributor.authorChawner, Samuel J.R.A.
dc.contributor.authorRodriguez-Moreno, Antonio
dc.contributor.authorvan den Bree, Marianne B.M.
dc.contributor.authorTesta, Giuseppe
dc.contributor.authorPetrakis, Spyros
dc.contributor.authorHarwood, Adrian J.
dc.date.accessioned2021-06-28T07:43:21Z
dc.date.available2021-06-28T07:43:21Z
dc.date.created2020-08-11T12:26:22Z
dc.date.issued2020
dc.identifier.issn2040-2392
dc.identifier.urihttps://hdl.handle.net/11250/2761493
dc.description.abstractPatients diagnosed with chromosome microdeletions or duplications, known as copy number variants (CNVs), present a unique opportunity to investigate the relationship between patient genotype and cell phenotype. CNVs have high genetic penetrance and give a good correlation between gene locus and patient clinical phenotype. This is especially effective for the study of patients with neurodevelopmental disorders (NDD), including those falling within the autism spectrum disorders (ASD). A key question is whether this correlation between genetics and clinical presentation at the level of the patient can be translated to the cell phenotypes arising from the neurodevelopment of patient induced pluripotent stem cells (iPSCs). Here, we examine how iPSCs derived from ASD patients with an associated CNV inform our understanding of the genetic and biological mechanisms underlying the aetiology of ASD. We consider selection of genetically characterised patient iPSCs; use of appropriate control lines; aspects of human neurocellular biology that can capture in vitro the patient clinical phenotype; and current limitations of patient iPSC-based studies. Finally, we consider how future research may be enhanced to maximise the utility of CNV patients for research of pathological mechanisms or therapeutic targets.en_US
dc.language.isoengen_US
dc.publisherBMCen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleCopy number variants (CNVs): a powerful tool for iPSC-based modelling of ASDen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright The Author(s). 2020en_US
dc.source.articlenumber42en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1186/s13229-020-00343-4
dc.identifier.cristin1822725
dc.source.journalMolecular Autismen_US
dc.relation.projectHelse Sør-Øst RHF: 2018094en_US
dc.relation.projectCOST (European Cooperation in Science and Technology): CA16210en_US
dc.identifier.citationMolecular Autism. 2020, 11, 42.en_US
dc.source.volume11en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal